Phototherapy and photochemotherapy for polymorphic light eruption desensitisation

a five year case series review from a university teaching hospital

A. Aslam, L. Fullerton, S. H. Ibbotson (Lead / Corresponding author)

Research output: Contribution to journalLetter

4 Citations (Scopus)
54 Downloads (Pure)

Abstract

Polymorphic light eruption (PLE) is the most common immunological photodermatosis, with a prevalence of 18% in Europe1. The pathogenesis of PLE appears to involve delayed cell mediated hypersensitivity and aberrant Langerhans cell function2,3. Phototherapy, using narrowband UVB (UVB) or psoralen-ultraviolet A (PUVA) photochemotherapy, is widely used for prophylactic desensitisation in PLE, with benefit experienced in 90% of patients4,5
Original languageEnglish
Pages (from-to)225-227
Number of pages3
JournalPhotodermatology, photoimmunology & photomedicine
Volume33
Issue number4
Early online date17 Apr 2017
DOIs
Publication statusPublished - 11 May 2017

Fingerprint

Phototherapy
Photochemotherapy
Teaching Hospitals
Light
Ficusin
Langerhans Cells
Hypersensitivity

Keywords

  • Phototherapy
  • Polymorphic light eruption
  • Desensitisation
  • UVB

Cite this

@article{1eaf519fa5364b05890e0601e0f30084,
title = "Phototherapy and photochemotherapy for polymorphic light eruption desensitisation: a five year case series review from a university teaching hospital",
abstract = "Polymorphic light eruption (PLE) is the most common immunological photodermatosis, with a prevalence of 18{\%} in Europe1. The pathogenesis of PLE appears to involve delayed cell mediated hypersensitivity and aberrant Langerhans cell function2,3. Phototherapy, using narrowband UVB (UVB) or psoralen-ultraviolet A (PUVA) photochemotherapy, is widely used for prophylactic desensitisation in PLE, with benefit experienced in 90{\%} of patients4,5",
keywords = "Phototherapy, Polymorphic light eruption, Desensitisation, UVB",
author = "A. Aslam and L. Fullerton and Ibbotson, {S. H.}",
note = "no funding info",
year = "2017",
month = "5",
day = "11",
doi = "10.1111/phpp.12310",
language = "English",
volume = "33",
pages = "225--227",
journal = "Photodermatology, photoimmunology & photomedicine",
issn = "0905-4383",
publisher = "Wiley",
number = "4",

}

TY - JOUR

T1 - Phototherapy and photochemotherapy for polymorphic light eruption desensitisation

T2 - a five year case series review from a university teaching hospital

AU - Aslam, A.

AU - Fullerton, L.

AU - Ibbotson, S. H.

N1 - no funding info

PY - 2017/5/11

Y1 - 2017/5/11

N2 - Polymorphic light eruption (PLE) is the most common immunological photodermatosis, with a prevalence of 18% in Europe1. The pathogenesis of PLE appears to involve delayed cell mediated hypersensitivity and aberrant Langerhans cell function2,3. Phototherapy, using narrowband UVB (UVB) or psoralen-ultraviolet A (PUVA) photochemotherapy, is widely used for prophylactic desensitisation in PLE, with benefit experienced in 90% of patients4,5

AB - Polymorphic light eruption (PLE) is the most common immunological photodermatosis, with a prevalence of 18% in Europe1. The pathogenesis of PLE appears to involve delayed cell mediated hypersensitivity and aberrant Langerhans cell function2,3. Phototherapy, using narrowband UVB (UVB) or psoralen-ultraviolet A (PUVA) photochemotherapy, is widely used for prophylactic desensitisation in PLE, with benefit experienced in 90% of patients4,5

KW - Phototherapy

KW - Polymorphic light eruption

KW - Desensitisation

KW - UVB

U2 - 10.1111/phpp.12310

DO - 10.1111/phpp.12310

M3 - Letter

VL - 33

SP - 225

EP - 227

JO - Photodermatology, photoimmunology & photomedicine

JF - Photodermatology, photoimmunology & photomedicine

SN - 0905-4383

IS - 4

ER -